Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Teun van Gelder

Showing results (81-90 of 324) with videos related to

Pageof 33
Sort By:
Expert Review of Clinical Immunology|November 14, 2019
Impact of low tacrolimus exposure and high tacrolimus intra-patient variability on the development of <i>de novo</i> anti-HLA donor-specific antibodies in kidney transplant recipientsAleixandra Mendoza Rojas, Dennis A Hesselink, Nicole M van Besouw, et al.
British Journal of Clinical Pharmacology|December 16, 2020
Retroperitoneal fibrosis and β-blocking agents: Is there an association?Hardjit Kharagjitsing, Rike van Eekeren, Eugène P van Puijenbroek, et al.
Therapeutic Drug Monitoring|December 1, 2004
Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategyReinier M van Hest, Ron A A Mathôt, Arnold G Vulto, et al.
British Journal of Clinical Pharmacology|June 6, 2024
Therapeutic drug monitoring of tacrolimus after kidney transplantation: trough concentration or area under curve-based monitoring?Teun van Gelder, Armin Gelinck, Soufian Meziyerh, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|October 15, 2011
ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantationNauras Shuker, Rachida Bouamar, Willem Weimar, et al.
Pharmacogenetics and Genomics|March 6, 2012
The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patientsLaure Elens, Rachida Bouamar, Dennis A Hesselink, et al.
Therapeutic Advances in Drug Safety|March 12, 2021
The use of a clinical decision support tool to assess the risk of QT drug-drug interactions in community pharmaciesFlorine A Berger, Heleen van der Sijs, Teun van Gelder, et al.
Therapeutic Drug Monitoring|July 17, 2004
Pharmacogenetics in immunosuppressive therapy: the best thing since TDM?Teun van Gelder, Dennis A Hesselink, Reinier M van Hest, et al.
Pharmacogenomics|November 3, 2017
SLCO1B1 rs4149056 genetic polymorphism predicting methotrexate toxicity in Chinese patients with non-Hodgkin lymphomaLin Yang, Hui Wu, Teun van Gelder, et al.
Exploratory Research in Clinical and Social Pharmacy|July 2, 2025
Using simulated patient methodology to assess sick day guidance in community pharmacy: The case of an elderly patient with diabetesTristan Coppes, Hetty Prins, Kees A van Amerongen, et al.
Pageof 33

Showing results (81-90 of 324) with videos related to

Sort By:
Pageof 33
Expert Review of Clinical Immunology|November 14, 2019
Impact of low tacrolimus exposure and high tacrolimus intra-patient variability on the development of <i>de novo</i> anti-HLA donor-specific antibodies in kidney transplant recipientsAleixandra Mendoza Rojas, Dennis A Hesselink, Nicole M van Besouw, et al.
British Journal of Clinical Pharmacology|December 16, 2020
Retroperitoneal fibrosis and β-blocking agents: Is there an association?Hardjit Kharagjitsing, Rike van Eekeren, Eugène P van Puijenbroek, et al.
Therapeutic Drug Monitoring|December 1, 2004
Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategyReinier M van Hest, Ron A A Mathôt, Arnold G Vulto, et al.
British Journal of Clinical Pharmacology|June 6, 2024
Therapeutic drug monitoring of tacrolimus after kidney transplantation: trough concentration or area under curve-based monitoring?Teun van Gelder, Armin Gelinck, Soufian Meziyerh, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|October 15, 2011
ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantationNauras Shuker, Rachida Bouamar, Willem Weimar, et al.
Pharmacogenetics and Genomics|March 6, 2012
The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patientsLaure Elens, Rachida Bouamar, Dennis A Hesselink, et al.
Therapeutic Advances in Drug Safety|March 12, 2021
The use of a clinical decision support tool to assess the risk of QT drug-drug interactions in community pharmaciesFlorine A Berger, Heleen van der Sijs, Teun van Gelder, et al.
Therapeutic Drug Monitoring|July 17, 2004
Pharmacogenetics in immunosuppressive therapy: the best thing since TDM?Teun van Gelder, Dennis A Hesselink, Reinier M van Hest, et al.
Pharmacogenomics|November 3, 2017
SLCO1B1 rs4149056 genetic polymorphism predicting methotrexate toxicity in Chinese patients with non-Hodgkin lymphomaLin Yang, Hui Wu, Teun van Gelder, et al.
Exploratory Research in Clinical and Social Pharmacy|July 2, 2025
Using simulated patient methodology to assess sick day guidance in community pharmacy: The case of an elderly patient with diabetesTristan Coppes, Hetty Prins, Kees A van Amerongen, et al.
Pageof 33